舌下免疫治疗对变应性鼻炎患者炎症因子及自噬的影响

宋小云, 张俊杰. 舌下免疫治疗对变应性鼻炎患者炎症因子及自噬的影响[J]. 临床耳鼻咽喉头颈外科杂志, 2020, 34(3): 230-234. doi: 10.13201/j.issn.2096-7993.2020.03.011
引用本文: 宋小云, 张俊杰. 舌下免疫治疗对变应性鼻炎患者炎症因子及自噬的影响[J]. 临床耳鼻咽喉头颈外科杂志, 2020, 34(3): 230-234. doi: 10.13201/j.issn.2096-7993.2020.03.011
SONG Xiaoyun, ZHANG Junjie. Effect of sublingual immunotherapy on inflammatory factors and autophagy in patients with allergic rhinitis[J]. J Clin Otorhinolaryngol Head Neck Surg, 2020, 34(3): 230-234. doi: 10.13201/j.issn.2096-7993.2020.03.011
Citation: SONG Xiaoyun, ZHANG Junjie. Effect of sublingual immunotherapy on inflammatory factors and autophagy in patients with allergic rhinitis[J]. J Clin Otorhinolaryngol Head Neck Surg, 2020, 34(3): 230-234. doi: 10.13201/j.issn.2096-7993.2020.03.011

舌下免疫治疗对变应性鼻炎患者炎症因子及自噬的影响

  • 基金项目:
    湖南省卫健委科研课题(No:B2019136)
详细信息

Effect of sublingual immunotherapy on inflammatory factors and autophagy in patients with allergic rhinitis

More Information
  • 目的 观察舌下免疫治疗对变应性鼻炎(AR)患者血清炎症因子IL-4、TNF-α及鼻黏膜自噬相关蛋白LC3水平的影响。方法 将40例AR患者随机分为舌下含服免疫治疗(SLIT)组(n=20)和对照组(n=20),SLIT组采用标准化尘螨疫苗SLIT联合常规药物进行为期2年的干预,对照组采用安慰剂及常规药物治疗。收集2组患者治疗前后的血液标本和下鼻甲黏膜;分析2组患者治疗前后的临床症状、体征和用药评分;ELISA检测治疗前后血清IL-4、TNF-α表达水平;Western blot检测治疗前后自噬相关蛋白LC3的表达情况。结果 SLIT组与对照组治疗前体征、症状、用药评分、年龄、性别、血清IL-4和TNF-α以及LC3表达情况差异无统计学意义(P>0.05)。治疗2年后,SLIT组患者体征、症状评分均较对照组显著改善;血清IL-4、TNF-α表达水平较对照组显著下降;自噬相关蛋白LC3表达情况显著低于对照组,均差异有统计学意义(P < 0.05)。结论 相比单纯药物治疗,SLIT联合常规药物治疗对AR患者的症状改善更加明显,SLIT在一定程度上能减轻AR患者的炎症水平以及自噬相关蛋白的表达。
  • 加载中
  • 图 1  2组患者治疗前后血清炎症因子IL-4(1a)和TNF-α(1b)表达水平

    图 2  2组患者治疗前后下鼻甲黏膜自噬相关蛋白LC3Ⅱ表达情况

    表 1  症状评分标准

    分级计分/分 喷嚏/个a) 流涕/次b) 鼻塞 鼻痒
    0 < 3 0 无症状 无症状
    1 3~5 ≤4 有意识吸气时感觉鼻塞 间断鼻痒
    2 6~10 5~9 间歇或交互性 蚁行感,可忍受
    3 ≥11 ≥10 几乎全天用口呼吸 蚁行感,难忍
    a)一次连续喷嚏个数;b)每日擤鼻次数。
    下载: 导出CSV

    表 2  2组患者治疗前后临床症状、体征和用药评分比较 中位数[25分位数~75分位数]

    组别 例数 症状评分 体征评分 用药评分
    治疗前 治疗后 治疗前 治疗后 治疗前 治疗后
    对照组 20 8.0(7.0~10.0) 3.0(1.0~5.0) 2.0(2.0~3.0) 1.0(1.0~3.0) 0.0(0.0~0.0) 0.0(0.0~0.0)
    SLIT组 20 9.0(8.0~10.0) 1.0(1.0~2.0) 2.0(2.0~4.0) 0.0(0.0~0.0) 0.0(0.0~0.0) 0.0(0.0~0.0)
    P >0.05 < 0.05 >0.05 < 0.05 >0.05 >0.05
    下载: 导出CSV
  • [1]

    Seidman M, Gurgel R, Lin S, et al. Clinical practice guideline: allergic rhinitis[J]. Otolaryngol Head Neck Surg, 2015, 152(1 Suppl): S1-43.

    [2]

    Meltzer E, Bukstein D. The economic impact of allergic rhinitis and current guidelines for treatment[J]. Ann Allergy Asthma Immunol, 2011, 106(2 Suppl): S12-16.

    [3]

    Mizushima N, Komatsu M. Autophagy: renovation of cells and tissues[J]. Cell, 2011, 147(4): 728-741. doi: 10.1016/j.cell.2011.10.026

    [4]

    Hammad H, Lambrecht B. Dendritic cells and epithelial cells: linking innate and adaptive immunity in asthma[J]. Nat Rev Immunol, 2008, 8(3): 193-204. doi: 10.1038/nri2275

    [5]

    Moldoveanu B, Otmishi O, Jani P, et al. Inflammatory mechanisms in the lung[J]. J Inflamm Res, 2009, 2: 1-11.

    [6]

    Holgate S. Pathogenesis of asthma[J]. Clin Exp Allergy, 2008, 38(6): 872-897. doi: 10.1111/j.1365-2222.2008.02971.x

    [7]

    Lambrecht B, Hammad H. The immunology of asthma[J]. Nat Immunol, 2015, 16(1): 45-56. doi: 10.1038/ni.3049

    [8]

    Bradding P, Walls A, Holgate S. The role of the mast cell in the pathophysiology of asthma[J]. J Allergy Clin Immunol, 2006, 117(6): 1277-1284. doi: 10.1016/j.jaci.2006.02.039

    [9]

    Levine B, Mizushima N, Virgin H. Autophagy in immunity and inflammation[J]. Nature, 2011, 469(7330): 323-335. doi: 10.1038/nature09782

    [10]

    Bousquet J, Khaltaev N, Cruz A, et al. Allergic Rhinitis and its Impact on Asthma(ARIA)2008 update(in collaboration with the World Health Organization, GA(2) LEN and AllerGen)[J]. Allergy, 2008, 63 Suppl 86: 8-160.

    [11]

    Mizushima N, Yoshimori T, Levine B. Methodsin mammalian autophagy research[J]. Cell, 2010, 140(3): 313-326. doi: 10.1016/j.cell.2010.01.028

    [12]

    李静, 李勇. 自噬在变应性鼻炎中的作用[J]. 中华临床免疫和变态反应杂志, 2018, 12(6): 437-640. https://www.cnki.com.cn/Article/CJFDTOTAL-OZHL201806029.htm

    [13]

    Ban G, Pham D, Trinh T, et al. Autophagy mechanisms in sputum and peripheral blood cells of patients with severe asthma: a new therapeutic target[J]. Clin Exp Allergy, 2016, 46(1): 48-59. doi: 10.1111/cea.12585

    [14]

    余杰情, 罗庆, 熊园平, 等. 变应性鼻炎中自噬相关基因LC3与ECP的表达及意义[J]. 临床耳鼻咽喉头颈外科杂志, 2019, 33(4): 322-325. https://www.cnki.com.cn/Article/CJFDTOTAL-LCEH201904009.htm

    [15]

    Saatian B, Rezaee F, Desando S, et al. Interleukin-4 and interleukin-13 cause barrier dysfunction in human airway epithelial cells[J]. Tissue Barriers, 2013, 1(2): E24333. doi: 10.4161/tisb.24333

    [16]

    Lee JK, Lee S, Baek MC, et al. Association between perfluorooctanoic acid exposure and degranulation of mast cells in allergic inflammation[J]. J Appl Toxicol, 2017, 37(5): 554-562. doi: 10.1002/jat.3389

    [17]

    Subramanian N, Bray M. Interleukin 1 releases histamine from human basophils and mast cells in vitro[J]. J Immunol, 1987, 138(1): 271-275.

    [18]

    Minai-Fleminger Y, Levi-Schaffer F. Mast cells and eosinophils: the two key effector cells in allergic inflammation[J]. Inflamm Res, 2009, 58(10): 631-638. doi: 10.1007/s00011-009-0042-6

    [19]

    Bischoff S. Role of mast cells in allergic and non-allergic immune responses: comparison of human and murine data[J]. Nat Rev Immunol, 2007, 7(2): 93-104. doi: 10.1038/nri2018

    [20]

    Shakoory B, Fitzgerald SM, Lee SA, et al. The role of human mast cell-derived cytokines in eosinophil biology[J]. J Interferon Cytokine Res, 2004, 24(5): 271-281. doi: 10.1089/107999004323065057

    [21]

    Wenzel S. Asthma phenotypes: the evolution from clinical to molecular approaches[J]. Nat Med, 2012, 18(5): 716-725. doi: 10.1038/nm.2678

  • 加载中

(2)

(2)

计量
  • 文章访问数:  1065
  • PDF下载数:  456
  • 施引文献:  0
出版历程
收稿日期:  2019-06-04
刊出日期:  2020-03-05

目录